摘要
目的研究泽菲与顺铂联合化疗方案治疗非小细胞肺癌（NSCLC）的临床疗效、生存期及毒副反应。方法入选患者均为Ⅲ、Ⅳ期非小细胞肺癌，初治33例，复治40例。泽菲1000mg／m^2，d1、d8；顺铂25mg／m^2，d1，d2，d3，21d为1个周期，2个周期后评价疗效及不良反应。结果73例可评价患者，完全缓解4例，部分缓解33例，总有效率50．7％；中位生存期9．2个月，1年生存率39．0％。Ⅲ／Ⅳ度白细胞减少症和血小板减少症发生率分别为15．1％和19．2％。结论泽菲与顺铂联合化疗方案治疗NSCLC有较好疗效，耐受性好。
Objective To study the clinical efficacy including patient survival and toxicity of a new combined chemotherapy with gemcitabine and cisplatin in treatment of non-small-cell lung cancer（NSCLC）. Methods Patients with stages-Ⅲ and-Ⅳ NSCLC were included. Thirty-three patients were untreated tumor cases,40 were recurrent tumor cases. The patients received gemcitabine 1000mg/m^2 on days 1,8 and cisplatin 25mg/m^2 on days 1,2 and 3. Each cycle took 21 days. The patients were evaluated after at least 2 cycles. Results Seventy-three patients were evaluable for the response. Four cases was CR, 33 cases was PR and the overall response rate was 50.7%. The median survival time was 9.2months and the 1-year survival rate was 39.0%. The main toxic effects were leukopenia（incidence of 15.1% for grade Ⅲ＋ Ⅳ）and thrombocytopenia（ incidence of 19.2% for grade Ⅲ＋ Ⅳ ）. Conclusions This regimen of gemcitabine and cisplatin is effective and well-tolerated in the treatment of advanced NSCLC.
出处
《中国肿瘤临床与康复》
2008年第2期142-143,共2页
Chinese Journal of Clinical Oncology and Rehabilitation
关键词
肺肿瘤/化学疗法
泽菲
顺铂
Lung neoplasms/chemotherapy
Gemcitabine
Cisplatin
